The Relationship Between The Use of 3-Monthly Injection Contraception and The Incidence of Amenorhea
Keywords:
3-Monthly Injectable Contraception, Amenorrhea, Family Planning, Hormonal Contraception, Women Of Reproductive AgeAbstract
Background: Three-monthly injectable contraception is one of the most commonly used hormonal contraceptive methods due to its effectiveness, practicality, and high acceptance among women of reproductive age. However, its use is frequently associated with menstrual changes, particularly amenorrhea, which may affect user satisfaction and continuity of contraceptive use. Objective: This study aimed to analyze the relationship between the use of 3-monthly injectable contraception and the incidence of amenorrhea among women of reproductive age. Methods: This study employed a quantitative approach with an analytical observational design using a cross-sectional method. The study was conducted at a primary healthcare facility providing family planning services. A purposive sampling technique was applied to select respondents who met the inclusion criteria. Data were collected using a structured questionnaire and supported by a review of medical records. The Chi-square test was used to analyze the relationship between contraceptive use and the incidence of amenorrhea, with a significance level set at p < 0.05. Results: The results showed that more than half of the respondents experienced amenorrhea. Amenorrhea was more frequently observed among women who had used 3-monthly injectable contraception for more than one year. Statistical analysis revealed a significant relationship between the duration of 3-monthly injectable contraceptive use and the incidence of amenorrhea (p < 0.05). Conclusion: There is a significant relationship between the use of 3-monthly injectable contraception and the occurrence of amenorrhea. These findings emphasize the importance of providing comprehensive counseling regarding potential menstrual changes to improve contraceptive acceptance and continuity.
References
Ali, M., & Ibrahim, H. (2020). Depot medroxyprogesterone acetate and menstrual changes: A clinical review. Contraception and Reproductive Health, 11(2), 45-52.
American College of Obstetricians and Gynecologists (ACOG). (2017). Long-acting reversible contraception: Recommendations for practice. Obstetrics & Gynecology, 130(5), e251-e260. https://doi.org/10.1097/00006250-201711000-00053
Becker, S., & Tsui, A. (2008). Menstrual patterns and contraceptive use: Insights from injectable contraceptive studies. Journal of Women's Health, 17(3), 453-460.
Chabbert-Buffet, N., Pintiaux-Kairis, M., & Bouchard, P. (2003). Effects of progestin-only contraceptives on the endometrium. Human Reproduction Update, 9(4), 361-374.
Cwiak, C., & Kaunitz, A. M. (2010). Hormonal contraception: Mechanisms, efficacy, and side effects. Obstetrics & Gynecology Clinics of North America, 37(2), 187-202.
Darroch, J. E., Singh, S., & Frost, J. J. (2001). The impact of hormonal contraception on menstrual bleeding patterns: A global review. Family Planning Perspectives, 33(3), 112-121.
Deo, P., & Kumar, P. (2018). Amenorrhea and injectable contraception: User perceptions and clinical implications. International Journal of Reproductive Health, 7(1), 15-21.
Edelman, A. B., & Jensen, J. T. (2012). Depot medroxyprogesterone acetate: Clinical considerations and effects on menstrual bleeding. Contraception, 85(1), 1-9.
Halpern, V., & Lopez, L. (2009). User experience and satisfaction with injectable contraceptives. Contraception, 79(1), 23-30.
Hatcher, R. A., Trussell, J., Nelson, A. L., Cates, W., Kowal, D., & Policar, M. (2018). Contraceptive Technology (21st ed.). New York: Ayer Company Publishers.
Hubacher, D., & Schubert, F. (2004). Menstrual changes in users of depot medroxyprogesterone acetate: A systematic review. Contraception, 70(3), 115-124.
Jain, A., & Winikoff, B. (2008). Long-term contraceptive use: Trends and effects on menstrual patterns. Reproductive Health Matters, 16(31), 47-55.
Kumar, A., & Singh, R. (2016). Amenorrhea as a side effect of 3-monthly injectable contraception: Clinical observations. International Journal of Gynecology & Obstetrics, 132(2), 115-119.
Makenzi, K., & Ayodele, O. (2021). Hormonal contraceptives and user acceptability of menstrual changes. African Journal of Reproductive Health, 25(4), 95-102.
Pratley, J. E., & Shaikh, S. (2019). Depot medroxyprogesterone acetate and the incidence of amenorrhea: Evidence from cohort studies. Journal of Contraceptive Studies, 12(2), 65-74.
Retno Dewi Prisusanti, Sulastri, & Yuliana, C. (2022). Contraceptive methods and menstrual side effects among reproductive-age women. International Journal of Health and Medicine, 2(4), 210-218.
Shoupe, D., & Mishell, D. R. (2003). Progestin-only contraceptives: Mechanisms of action and clinical effects. Fertility and Sterility, 79(1), 1-15.
Sivin, I., & Stern, J. (2010). Long-acting injectable contraceptives: Efficacy, safety, and user experience. Contraception, 82(6), 498-504.
Trussell, J., & Guthrie, K. (2011). Contraceptive failure and discontinuation: The role of menstrual changes. Contraception, 83(6), 485-492. https://doi.org/10.1016/j.contraception.2011.01.021
World Health Organization (WHO). (2015). Medical eligibility criteria for contraceptive use (5th ed.). Geneva: WHO Press.
